ArticleRMD open2026
Immunoprecipitation-mass spectrometry reveals known and novel (NatC,
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn a fraction of patients with rheumatoid arthritis (RA), antinuclear antibodies (ANA) are present. However, in most ANA-positive samples from patients with RA, no autoantigens can be identified. We aimed to characterise the ANA landscape in RA and to identify known and novel autoantigens using an unbiased immunoprecipitation-mass spectrometry (IP-MS) approach.
methodsSera from 51 ANA-positive, DMARD-naïve patients with RA were analysed by IP-MS using HeLa nuclear or cytoplasmic extracts (depending on the ANA staining pattern). Immunoprecipitated proteins were digested and identified using liquid chromatography coupled with MS. The prevalence of new or unfamiliar autoantigens was assessed in 43 healthy individuals and 88 ANA-positive individuals with a systemic rheumatic disease (systemic lupus erythematosus, Sjögren's disease, systemic sclerosis and idiopathic inflammatory myopathy).
resultsAutoantigens were detected in 10 of 51 RA samples (in 2/29 with titre 1/160, in 4/12 with titre 1/320 and in 4/10 with titre ≥1/640). Autoantigens identified included SSA-Ro60, SSB-La, Ku, fibrillarin, components of the mitochondrial multienzyme complex, protein argonaute 1, 2, 3 and T-cell restricted intracellular antigen 1 and TIA-1-related protein. Two novel autoantigens were discovered: the N-terminal acetyltransferase C (NatC) complex and mitochondrial chaperone BCS1. Neither NatC nor BCS1 was detected in healthy individuals or individuals with other systemic rheumatic diseases.
conclusionIP-MS revealed a diverse spectrum of autoantigens in patients with ANA-positive RA, including previously unreported targets. These findings expand our knowledge of RA-associated autoimmunity and highlight antibodies to NatC and BCS1 as potential novel biomarkers. Further studies are needed to assess their clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.